Allergy Asthma Immunol Res.  2017 Mar;9(2):99-100. 10.4168/aair.2017.9.2.99.

Size of Inhaled Corticosteroid and Small Airway Inflammation in Asthma

• Park CS

• KMID: 2413382
• DOI: http://doi.org/10.4168/aair.2017.9.2.99

Abstract

No abstract available.

MeSH Terms

Asthma*
Inflammation*

Reference

1. Global Initiative for Asthma. Global strategy for asthma management and prevention, revised 2016. Available from: http://www.ginasthma.org.

2. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline (SIGN 141). London: British Thoracic Society;2014. cited 2016 Apr 28. Available from: http://www.sign.ac.uk/pdf/SIGN141.pdf.

3. National Heart, Lung, and Blood Institute (US). Expert panel report 3: guidelines for the diagnosis and management of asthma: national asthma education and prevention program [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute;2007. cited 2016 Apr 28. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.

4. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway responsiveness and clinical asthma in nonsteroid dependent asthmatics. Am Rev Respir Dis. 1990; 142:832–836.

5. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991; 325:388–392.

6. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161:1720–1745.

7. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332–336.

8. Green M. How big are the bronchioles? St Thomas Hosp Gaz. 1967; 63:136–139.

9. Hamid Q. Pathogenesis of small airways in asthma. Respiration. 2012; 84:4–11.

10. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res. 2014; 6:376–388.

11. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013; 131:646–657.

12. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37:1308–1331.

13. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med. 2005; 18:379–385.

14. Postma DS, Dekhuijzen R, van der Molen T, Martin RJ, van Aalderen W, Roche N, et al. Asthma-related outcomes in patients initiating extrafine ciclesonide or fine-particel inhaled corticosteroids. Allergy Asthma Immunol Res. 2017; 9:116–125.

15. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006; 100:375–384.

16. Leach CL, Bethke TD, Boudreau RJ, Hasselquist BE, Drollmann A, Davidson P, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med. 2006; 19:117–126.

17. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007; 62:1182–1188.

18. Dahl R, Nielsen LP. Steroids: an overview. In : Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy, and COPD. Basel: Karger;2001. p. 86–90.